Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 101–200 of 793
Hypoglycemia in Type 2 Diabetes - More Common Than You Think: A Continuous Glucose Monitoring Study
Gehlaut, R. R., Dogbey, G. Y., Schwartz, F. L., Marling, C. R., & Shubrook, J. H. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815581052 · Cited by 131
“Hypoglycemia is often one of the major limiting factors in intensive glycemic control for both type 1 diabetes (T1DM) and type 2 diabetes (T2DM).(1) Although hypoglycemia is well recognized in the management of T1DM, less is known about the true prevalence of hypoglycemia in patients with T2DM.”
BackgroundCerebral glucose metabolism in diabetes mellitus
McCall, A. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.052 · Cited by 146
Prediction of Severe Hypoglycemia
Cox, D. J., Gonder-Frederick, L., Ritterband, L., Clarke, W., & Kovatchev, B. P. (2007) · Diabetes Care · doi:10.2337/dc06-1386 · Cited by 129
Breton, M. D., Brown, S. A., Karvetski, C. H., Kollar, L., Topchyan, K. A., Anderson, S. M., & Kovatchev, B. P. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0333 · Cited by 128
Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
“Glucagon is the most important hyperglycemic hormone of the body (Lefebvre 1996; Cryer 2002).”
BackgroundBiester, T., Kordonouri, O., Holder, M., Remus, K., Kieninger-Baum, D., Wadien, T., & Danne, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0349 · Cited by 128
“Together with the metabolic effects caused by hormonal counter-regulatory reactions in response to hypoglycemic events, all of these factors contribute to hypoglycemia having a negative impact on glycemic control.(9,10)”
BackgroundDeRosa, M. A., & Cryer, P. E. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00539.2003 · Cited by 126
“IN THE SETTING OF ENDOGENOUS INSULIN DEFICIENCY, relative or absolute therapeutic insulin excess, and absent glucagon responses to falling plasma glucose concentrations, reduced adrenomedullary epinephrine responses to a given level of hypoglycemia cause defective glucose counterregulation, and reduced sympathoadrenal…”
BackgroundSelf-citationRSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 125
Bergenstal, R. M., Bailey, T. S., Rodbard, D., Ziemen, M., Guo, H., Muehlen-Bartmer, I., & Ahmann, A. J. (2017) · Diabetes Care · doi:10.2337/dc16-0684 · Cited by 122
“It is also well recognized that hypoglycemia is a limiting factor when intensifying insulin therapy (1).”
BackgroundDevelopment of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Lapuerta, P., Zambrowicz, B., Strumph, P., & Sands, A. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114563304 · Cited by 119
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
Borse, S., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2020) · Medical Principles and Practice · doi:10.1159/000511002 · Cited by 173
Green, A. J., Fox, K., & Grandy, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.002 · Cited by 124
“[1] Cryer PE.”
BackgroundChan, O., Zhu, W., Ding, Y., McCrimmon, R. J., & Sherwin, R. S. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-0958 · Cited by 113
The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Aroda, V. R., & Ratner, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1202 · Cited by 112
“10 μg bid added to SU and/or MET [36] 28 n/a 10 n/a 12 n/a”
BackgroundInfluentialExperimental and clinical aspects of melatonin and clock genes in diabetes
Peschke, E., Bähr, I., & Mühlbauer, E. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12240 · Cited by 111
DePaula, A. L., Macedo, A. L. V., Mota, B., & Schraibman, V. (2008) · Surgical Endoscopy · doi:10.1007/s00464-008-0156-x · Cited by 111
“However, iatrogenic hypoglycemia in advanced T2DM may represent a limiting factor to this strategy [18].”
BackgroundGlycemic Variability: Risk Factors, Assessment, and Control
Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819826111 · Cited by 124
“Consequently, hypoglycemia has been implicated as the primary barrier to tight control.(18,19) Therefore, people with diabetes face a lifelong optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia.”
BackgroundCost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden
Jönsson, L., Bolinder, B., & Lundkvist, J. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00100.x · Cited by 115
Glucagon secretion from pancreatic α-cells
Briant, L., Salehi, A., Vergari, E., Zhang, Q., & Rorsman, P. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1156789 · Cited by 109
“This compromised physiological and behavioural response to falling blood glucose concentrations is arguably the more fatal arm of impaired glycaemic control in T2DM, with hypoglycaemia being a major cause of mortality in insulin-treated patients (16).”
BackgroundDual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 108
Subcutaneous insulin: pharmacokinetic variability and glycemic variability
Guerci, B., & Sauvanet, J.-P. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)88263-1 · Cited by 123
Kølendorf, K., Ross, G. P., Pavlic‐Renar, I., Perriello, G., Philotheou, A., Jendle, J., Gall, M., & Heller, S. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01862.x · Cited by 108
Chan, O., Cheng, H., Herzog, R., Czyzyk, D., Zhu, W., Wang, A., McCrimmon, R. J., Seashore, M. R., & Sherwin, R. S. (2008) · Diabetes · doi:10.2337/db07-1559 · Cited by 107
“Hence, iatrogenic hypoglycemia remains the major limiting factor in the proper management of circulating glucose in both patients with type 1 and type 2 diabetes (3).”
BackgroundHanefeld, M. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-20 · Cited by 106
Physical Activity into the Meal Glucose—Insulin Model of Type 1 Diabetes: In Silico Studies
Dalla Man, C., Breton, M. D., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300107 · Cited by 107
“J Diabetes Sci Technol 2009;3(1):56-67”
KATP-channels and glucose-regulated glucagon secretion
Rorsman, P., Salehi, A. A., Abdulkader, F., Braun, M., & MacDonald, P. E. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.07.003 · Cited by 116
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M., Pihoker, C., Donaghue, K. C., Hanås, R., Swift, P. G. F., & KLINGENSMITH, G. J. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00352.x · Cited by 123
Breton, M. D., & Kovatchev, B. P. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400309 · Cited by 103
Onishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102
Tsujimoto, T., Yamamoto-Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M., & Noda, M. (2014) · Diabetes Care · doi:10.2337/dc13-0701 · Cited by 103
“This result might be partly attributable to the fact that T1DM patients typically experience frequent episodes of hypoglycemia and their counterregulatory response to hypoglycemia becomes blunted as a result of hypoglycemia-associated autonomic failure (22,24).”
BackgroundZhou, H., Tran, P. O. T., Yang, S., Zhang, T., LeRoy, E., Oseid, E., & Robertson, R. P. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1482 · Cited by 101
“These combined defects render hypoglycemia a major obstacle to the completely successful management of diabetes with exogenous insulin and thereby limit the possibility of preventing long-term diabetes complications (11,12).”
Hypothalamic–Pituitary–Adrenal and Autonomic Nervous System Functioning in Fibromyalgia
Adler, G. K., & Geenen, R. (2005) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.10.002 · Cited by 117
“Enhanced responses may be associated with increased exercise performance and reduced fatigue [42,43], whereas reduced neuroendocrine and ANS stress responses may result in inadequate physiologic responses, as occurs in patients who have HAAF [39,40].”
BackgroundHNF1 β/TCF2 mutations impair transactivation potential through altered co-regulator recruitment
Barbacci, E., Chalkiadaki, A., Masdeu, C., Haumaître, C., Lokmane, L., Loirat, C., Cloarec, S., Talianidis, I., Bellanné‐Chantelot, C., & Cereghini, S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh338 · Cited by 100
Briant, L. J. B., Dodd, M. S., Chibalina, M. V., Rorsman, N. J. G., Johnson, P. R. V., Carmeliet, P., Rorsman, P., & Knudsen, J. G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.035 · Cited by 98
“The abnormalities in glucagon secretion in T2DM include both loss of adequate suppression under hyperglycemic conditions (Cryer, 2002, 2008; Cryer et al., 2003; Dunning et al., 2005; D’Alessio, 2011; Unger and Cherrington, 2012) and insufficient release 3300 Cell Reports 23, 3300–3311, June 12,…”
BackgroundBreton, M. D., Patek, S. D., Lv, D., Schertz, E., Robic, J., Pinnata, J., Kollar, L., Barnett, C., Wakeman, C., Oliveri, M., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0079 · Cited by 98
“15,16 Thus, patients with T1DM face a life-long optimization problem: reduce average glucose levels and postprandial hyperglycemia while simultaneously avoiding hypoglycemia.”
Song, S., & Roy, S. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25895 · Cited by 109
“Hypoglycemia can result in cognitive impairment, unconsciousness, seizures, and death (Cryer, 2002).”
BackgroundVora, J., Christensen, T., Rana, A., & Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0076-9 · Cited by 96
“However, hypoglycemia and the fear of hypoglycemia, as well as weight gain, impair both patients’ and physicians’ willingness to titrate insulin to the doses required to achieve guideline-recommended target levels of glycemia [1–3].”
BackgroundFarngren, J., Persson, M., Schweizer, A., Foley, J. E., & Ahrén, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2332 · Cited by 95
“Thus, it has been repeatedly demonstrated that hypoglycemia is the limiting factor achieving good glycemic control in T1D (25).”
Hamilton, A., Zhang, Q., Salehi, A., Willems, M., Knudsen, J. G., Ringgaard, A. K., Chapman, C. E., Gonzalez-Alvarez, A., Surdo, N. C., Zaccolo, M., et al. (2018) · Diabetes · doi:10.2337/db17-1102 · Cited by 94
“The ability of the “fight-or-flight” hormone adrenaline to increase plasma glucose levels by stimulating liver gluconeogenesis is in part mediated by glucagon, the body’s principal hyperglycemic hormone (1).”
BackgroundHypoglycemia Prediction and Detection Using Optimal Estimation
Palerm, C. C., Willis, J. P., Desemone, J., & Bequette, B. W. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.3 · Cited by 94
Wang, C., Lv, L., Yang, Y., Chen, D., Liu, G., Chen, L., Song, Y., He, L., Li, X., Tian, H., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04205.x · Cited by 94
Effects of advanced carbohydrate counting in patients with Type 1 diabetes: a systematic review
Schmidt, S., Schelde, B., & Nørgaard, K. (2014) · Diabetic Medicine · doi:10.1111/dme.12446 · Cited by 94
Ratzki-Leewing, A., Harris, S. B., Mequanint, S., Reichert, S. M., Belle Brown, J., Black, J. E., & Ryan, B. L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000503 · Cited by 90
Rorsman, P., Ramracheya, R. D., Rorsman, N. J. G., & Zhang, Q. (2014) · Diabetologia · doi:10.1007/s00125-014-3279-8 · Cited by 101
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 92
Ly, T. T., Gallego, P. H., Davis, E. A., & Jones, T. W. (2009) · Diabetes Care · doi:10.2337/dc09-0541 · Cited by 93
“Hypoglycemia unawareness is defined as the onset of neuroglycopenia before autonomic activation (1).”
BackgroundGustavsson, N., & Han, W. (2009) · Bioscience Reports · doi:10.1042/bsr20090031 · Cited by 91
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Philis‐Tsimikas, A., Skjøth, T. V., Rana, A., Mathieu, C., & The BEGIN Once Long Trial Investigators (2013) · Diabetic Medicine · doi:10.1111/dme.12303 · Cited by 89
The GluCre‐ROSA26EYFP mouse: A new model for easy identification of living pancreatic α‐cells
Quoix, N., Cheng-Xue, R., Guiot, Y., Herrera, P. L., Henquin, J.-C., & Gilon, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.07.068 · Cited by 90
Hughes, C. S., Patek, S. D., Breton, M. D., & Kovatchev, B. P. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400513 · Cited by 89
Nocturnal Hypoglycemia: Clinical Manifestations and Therapeutic Strategies Toward Prevention
Allen, K. V., & Frier, B. M. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.530 · Cited by 104
Palerm, C. C., & Bequette, B. W. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100505 · Cited by 89
“The model [Equation (1)] can then be used to estimate blood glucose into the future.”
Drug-Induced Hypoglycaemia: An Update
Salem, C. B., Fathallah, N., Hmouda, H., & Bouraoui, K. (2010) · Drug Safety · doi:10.2165/11538290-000000000-00000 · Cited by 97
Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
Heise, T., & Meneghini, L. F. (2014) · Endocrine Practice · doi:10.4158/ep13090.ra · Cited by 87
Hendrieckx, C., Halliday, J. A., Bowden, J. P., Colman, P. G., Cohen, N. D., Jenkins, A. J., & Speight, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.005 · Cited by 93
An Overview of Hypoglycemia in the Critically Ill
Lacherade, J.-C., Jacqueminet, S., & Preiser, J.-C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300603 · Cited by 86
A Review of Types 1 and 2 Diabetes Mellitus and Their Treatment with Insulin
Salsali, A., & Nathan, M. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200607000-00012 · Cited by 85
Control to Range for Diabetes: Functionality and Modular Architecture
Kovatchev, B., Patek, S., Dassau, E., Doyle, F. J., Magni, L., De Nicolao, G., Cobelli, C., & Juvenile Diabetes Research Foundation Artificial Pancreas Consortium (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300509 · Cited by 83
Haidar, A., Messier, V., Legault, L., Ladouceur, M., & Rabasa‐Lhoret, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12880 · Cited by 81
“Hypoglycaemia remains the major barrier to achieving glycaemic targets.(2) Non-severe hypoglycaemia can trigger adrenergic and neurologic symptoms, and occurs 2 to 3 times per patient per week.”
BackgroundLy, T. T., Hewitt, J., Davey, R. J., Lim, E. M., Davis, E. A., & Jones, T. W. (2011) · Diabetes Care · doi:10.2337/dc10-1042 · Cited by 81
“ypoglycemia unawareness is defined as the onset of neuroglycopenia before autonomic activation (1).”
BackgroundO'Connell, S. M., Cooper, M. N., Bulsara, M. K., Davis, E. A., & Jones, T. W. (2011) · Diabetes Care · doi:10.2337/dc11-0748 · Cited by 81
“The threat of hypoglycemia as a consequence of insulin treatment is a major barrier to optimizing glycemic control in type 1 diabetes (1).”
BackgroundCooper, M. N., O'Connell, S. M., Davis, E. A., & Jones, T. W. (2013) · Diabetologia · doi:10.1007/s00125-013-2982-1 · Cited by 81
“5 in 2006, before levelling off and showing no significant change from 2006 through to 2011, following the trend illustrated in our most recent report [2, 3].”
BackgroundHermanns, N., Kulzer, B., Kubiak, T., Krichbaum, M., & Haak, T. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.710 · Cited by 80
Impact of Hypoglycemia on Brain Metabolism During Diabetes
Rehni, A. K., & Dave, K. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1044-6 · Cited by 89
“Therefore, drug therapy-related hypoglycemia is an important problem in the management of both type 1 (T1D) and type 2 diabetes (T2D) [5].”
InfluentialOlsen, S. E., Åsvold, B. O., Frier, B. M., Aune, S. E., Hansen, L. I., & Bjørgaas, M. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12496 · Cited by 78
Quoix, N., Cheng-Xue, R., Mattart, L., Zeinoun, Z., Guiot, Y., Beauvois, M. C., Henquin, J.-C., & Gilon, P. (2009) · Diabetes · doi:10.2337/db07-1298 · Cited by 78
“Glucagon secretion is normally inhibited by hyperglycemia and stimulated by hypoglycemia, but alterations of its physiological regulation contribute to abnormal glucose homeostasis in diabetes (1,2).”
Wang, Y., Fu, H., & Zeng, D. (2018) · Journal of the American Statistical Association · doi:10.1080/01621459.2017.1303386 · Cited by 78
“While the progressive nature of the disease requires an escalating sequence of medications or dose of insulin, the risk of hypoglycemia and other adverse events may increase with the intensified treatment (Cryer, 2002).”
BackgroundLuippold, G., Klein, T., Mark, M., & Grempler, R. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01569.x · Cited by 76
“Insulin injections for T1DM treatment are associated with potential side effects, such as hypoglycaemia [6,7] and weight gain [10].”
BackgroundOral Insulin Delivery in a Physiologic Context: Review
Arbit, E., & Kidron, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817691303 · Cited by 83
Knudsen, J. G., Hamilton, A., Ramracheya, R., Tarasov, A. I., Brereton, M., Haythorne, E., Chibalina, M. V., Spégel, P., Mulder, H., Zhang, Q., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.003 · Cited by 77
“Therefore, hypoglycemia has been referred to as the limiting factor in diabetes therapy (Cryer, 2002).”
BackgroundPrediction and prevention of hypoglycaemic events in type-1 diabetic patients using machine learning
Vehí, J., Contreras, I., Oviedo, S., Biagi, L., & Bertachi, A. (2020) · Health Informatics Journal · doi:10.1177/1460458219850682 · Cited by 76
Harris, S., Mamdani, M., Galbo-Jørgensen, C. B., Bøgelund, M., Gundgaard, J., & Groleau, D. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.09.001 · Cited by 76
Bode, B. W., Testa, M. A., Magwire, M., Hale, P. M., Hammer, M., Blonde, L., Garber, A., & on behalf of the LEAD‐3 Study Group (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01196.x · Cited by 76
“Although insulin therapy has been shown to improve the health outcomes of patients with type 2 diabetes, its initiation and intensification are commonly postponed because of concerns over the burden of daily injections, regimen complexity and the often attendant hypoglycaemia and weight gain [1,2].”
BackgroundMelatonin stimulates glucagon secretion in vitro and in vivo: Melatonin and glucagon interactions
Bähr, I., Mühlbauer, E., Schucht, H., & Peschke, E. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00848.x · Cited by 75
“The cause of this diabetes-associated disturbance is seen in the loss of insulin secretion and consecutive absent inhibition of glucagon release [52].”
BackgroundCAPS1 and CAPS2 Regulate Stability and Recruitment of Insulin Granules in Mouse Pancreatic β Cells
Speidel, D., Salehi, A., Obermueller, S., Lundquist, I., Brose, N., Renström, E., & Rorsman, P. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.009 · Cited by 75
Marrett, E., Stargardt, T., Mavros, P., & Alexander, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01123.x · Cited by 75
Glucagon secretion and signaling in the development of diabetes
Gaisano, H. Y., MacDonald, P. E., & Vranic, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00349 · Cited by 75
“Rizza, 1991; Cryer, 2002; Dunning and Gerich, 2007; Quesada et al., 2008).”
BackgroundEcological Momentary Assessment in Behavioral Medicine
Robbins, M. L., & Kubiak, T. (2014) · The Handbook of Behavioral Medicine · doi:10.1002/9781118453940.ch20 · Cited by 73
“Perceiving fluctuations in blood glucose and especially recognizing low blood glucose levels (hypoglycemia) in time is essential for people with type 1 diabetes (Cryer, 2002).”
Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes
Cha, S.-A., Yun, J.-S., Lim, T.-S., Hwang, S., Yim, E.-J., Song, K.-H., Yoo, K.-D., Park, Y.-M., Ahn, Y.-B., & Ko, S.-H. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.3.202 · Cited by 74
“Hypoglycemia is a well-known acute complication of diabetes treatment and regarded as a major obstacle to reach glycemic targets in patients with type 2 diabetes [1].”
BackgroundWeintrob, N., Schechter, A., Benzaquen, H., Shalitin, S., Lilos, P., Galatzer, A., & Phillip, M. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.7.677 · Cited by 73
“Furthermore, the presence of recurrent mild events of hypoglycemia predisposes patients to hypoglycemia unawareness, thereby placing them at increased risk of severe hypoglycemia.(20) The smaller AUCs for hypoglycemia during CSII in the present study might explain the significant decrease in the rate of severe hypogly…”
ResultPhysical Activity—The Major Unaccounted Impediment to Closed Loop Control
Breton, M. D. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200127 · Cited by 73
Bolo, N. R., Musen, G., Jacobson, A. M., Weinger, K., McCartney, R. L., Flores, V., Renshaw, P. F., & Simonson, D. C. (2011) · Diabetes · doi:10.2337/db11-0506 · Cited by 72
“When severe, they can lead to seizures and coma (1).”
BackgroundDefining hypoglycaemia: what level has clinical relevance?
Frier, B. M. (2009) · Diabetologia · doi:10.1007/s00125-008-1209-3 · Cited by 71
Abdelrahim, D. N., Faris, M. E., Hassanein, M. M., Shakir, A. Z., Yusuf, A. M., Almeneessier, A. S., & BaHammam, A. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624423 · Cited by 75
A Review of Closed-Loop Algorithms for Glycemic Control in the Treatment of Type 1 Diabetes
El Youssef, J., Castle, J., & Ward, W. K. (2009) · Algorithms · doi:10.3390/a2010518 · Cited by 69
Unperturbed islet α‐cell function examined in mouse pancreas tissue slices
Huang, Y., Rupnik, M., & Gaisano, H. Y. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.200345 · Cited by 68
“…in the initial characterization of normal α-cells is required for subsequent work directed at examining the precise mechanisms underlying dysregulated glucagon secretion resulting from diabetes, which disrupts α-cells per se and also intra-islet integrative physiology (Gerich, 1988; Cryer, 2002).”
BackgroundType 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 77
Morbidity of hypoglycemia in type 1 diabetes
Frier, B. M. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.008 · Cited by 80
“Therefore, hypoglycemia is a limiting factor in the successful metabolic control of diabetes and must not be regarded simply as a necessary consequence of the effort to maintain strict glycemic control [2].”
BackgroundUCP2 Regulates the Glucagon Response to Fasting and Starvation
Allister, E. M., Robson-Doucette, C. A., Prentice, K. J., Hardy, A. B., Sultan, S., Gaisano, H. Y., Kong, D., Gilon, P., Herrera, P. L., Lowell, B. B., et al. (2013) · Diabetes · doi:10.2337/db12-0981 · Cited by 67
Sanmiguel, C. P., Conklin, J. L., Cunneen, S. A., Barnett, P. S., Phillips, E. H., Kipnes, M. S., Pilcher, J., & Soffer, E. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300445 · Cited by 68
Zick, R., Petersen, B., Richter, M., Haug, C., & on Behalf of the SAFIR Study Group (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0230 · Cited by 64
“4 Though the frequency of overall episodes of hypoglycemia is lower in patients with T2DM versus Type 1 diabetes (T1DM), 5,6 studies indicate that rates of hypoglycemia are associated with duration rather than type of disease.”
Davies, M. J., Lavalle-Gonzalez, F. J., Storms, F., Gomis, R., & AT.LANTUS Study Group (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00873.x · Cited by 72
Emerging Roles for Glycogen in the CNS
Waitt, A. E., Reed, L., Ransom, B. R., & Brown, A. M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00073 · Cited by 65
Pedersen, M. G., Ahlstedt, I., El Hachmane, M. F., & Göpel, S. O. (2016) · Scientific Reports · doi:10.1038/srep31214 · Cited by 64
“∞ − m (V) [1 exp((V V )/S )] (4) X, mX mX 1”
Geelhoed-Duijvestijn, P. H., Pedersen-Bjergaard, U., Weitgasser, R., Lahtela, J., Jensen, M. M., & Östenson, C.-G. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.852098 · Cited by 64
Uncovering undetected hypoglycemic events
Unger, J. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s29367 · Cited by 62
“In fact, hypoglycemia is a key limiting factor in the successful glycemic management of many diabetes patients, with recent studies indicating a substantial prevalence of hypoglycemic events, not only in patients with type 1 diabetes mellitus, but also in patients with type 2 diabetes mellitus, particularly in those w…”
BackgroundEffect of gender on treatment outcomes in type 2 diabetes mellitus
McGill, J. B., Vlajnic, A., Knutsen, P. G., Recklein, C., Rimler, M., & Fisher, S. J. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.001 · Cited by 61
“Hypoglycemia remains the major barrier to glycemic control in people with diabetes [14].”
BackgroundInfluentialAl Khalifah, R. A., Alnhdi, A., Alghar, H., Alanazi, M., & Florez, I. D. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12493 · Cited by 61
“One study included girls with polycystic ovarian syndrome concomitant with T1DM.25 All studies used placebo as comparator, no study compared Metformin to a control group with no intervention, or a co-intervention.”
BackgroundInfluentialLoss of mTORC1 signaling alters pancreatic α cell mass and impairs glucagon secretion
Bozadjieva-Kramer, N., Blandino-Rosano, M., Chase, J., Dai, X., Cummings, K., Gimeno, J., Dean, E. D., Powers, A. C., Gittes, G. K., Rüegg, M. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90004 · Cited by 65
Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes.
de Galan, B. E., Schouwenberg, B. J. J. W., Tack, C. J., & Smits, P. (2006) · PubMed · Cited by 83
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.